Topamax gets label expansion


The FDA approves Topamax (topiramate) for use in adolescents ages 12 to 17. This is the first such clearance for a migraine headache drug for this age group.

Johnson & Johnson's (JNJ) Janssen Pharmaceuticals unit manufactures the product.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs